Bifulco Maurizio, Malfitano Anna Maria, Proto Maria Chiara, Santoro Antonietta, Caruso Maria Gabriella, Laezza Chiara
Dipartmento di Scienze Farmaceutiche, Università di Salerno, 84084 Fisciano, SA, Italy.
Anticancer Agents Med Chem. 2008 Feb;8(2):200-4. doi: 10.2174/187152008783497028.
A common modification of eukaryotic and bacterial tRNAs is isopentenylation of the adenosine at position 37, with the formation of isopentenyladenosine. N6-Isopentenyladenosine plays a major role in posttranscriptional processes, including the function of mammalian selenocysteine tRNA. This molecule seems to have metabolic effects that, for its relationships with isoprenoid metabolism and its direct biological activities, affects mammalian cell cytoskeleton, proliferation and apoptosis. In addition, preliminary clinical observation seems to indicate a possible use of N6-Isopentenyladenosine as anticancer drug.
真核生物和细菌的tRNA常见的一种修饰是37位腺苷的异戊烯基化,形成异戊烯基腺苷。N6-异戊烯基腺苷在转录后过程中起主要作用,包括哺乳动物硒代半胱氨酸tRNA的功能。该分子似乎具有代谢效应,因其与类异戊二烯代谢的关系及其直接的生物学活性,会影响哺乳动物细胞的细胞骨架、增殖和凋亡。此外,初步临床观察似乎表明N6-异戊烯基腺苷可能用作抗癌药物。